From: Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer
 | O'Brien 2006 | Von Pawel 1999 | Von Pawel 2001 | Eckardt 2007 |
---|---|---|---|---|
 | Oral topotecan vs BSC | IV topotecan vs CAV | Oral vs IV topotecan | Oral vs IV topotecan |
Overall survival (median) | 25.9 (18.3 to 31.6) weeks vs 13.9 (11.1 to 18.6) weeks | 25 (0.4 to 90.7) weeks vs 24.7 (1.3 to 101.3) weeks | 32.3 (0.4-69.1) weeks vs 25.1 (0.6-65.1) weeks | 33.0 (29.1 to 42.4) weeks vs 35.0 (31.0 to 37.4) weeks |
Overall survival [hazard ratio] | 0.61 (0.43 to 0.87) | 1.04 (0.78 to 1.40)†| Risk ratio 0.90 (0.55 to 1.47) | 0.98 (0.77 to 1.25) |
Progression free survival | ||||
Time to progression | 16.3 (12.9 to 20.0) weeks* | 13.3 (0.4 to 55.1) weeks vs 12.3 (0.1 to 75.3) weeks | 15 weeks vs 13 weeks | Â |
Response rate [risk ratio] | Â | 1.33 (0.79 to 2.25)$ | 1.56 (0.69 to 3.50)$ | 0.84 (0.53 to 1.31)$ |
Response rate | 7%* | 24.3% (16.2 to 32.4) vs18.3% (10.8 to 25.7); difference 6.0% (-6 to 18) | 23% vs 15% difference 8.3% (-6.6% to 23.1%) | 18.3% (12.2 to 24.4) vs 21.9% (15.3 to 28.5%) difference - 3.6% (-12.6% to 5.5%) |
Complete response | Â | 0% vs 1% | Â | Â |
Response duration | Â | 14.4 (9.4 to 50.1) weeks vs 15.3 (8.6 to 69.9) weeks | 18 weeks vs 14 weeks | 18.3 weeks vs 25.4 weeks |
Stable disease | 44%* | 19.6% vs 11.5%; OR 1.87 (0.87 to 4.03)$ | Â | Â |
Quality of Life | Difference in rate of change EQ-5 D 0.15 (0.05 to 0.25) in favour of topotecan | Â | Â | FACT-L total score (change from baseline) -5.07 (-7.49 to -2.65) vs -5.67 (-8.05 to 3.28); difference 0.59 (-2.38 to 3.57)# |